BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Conference Call: A Deep Dive
On March 27, 2025, at 4:30 PM ET, BioRestorative Therapies, Inc. (BRTX) held its Q4 2024 earnings conference call. The call was hosted by Stephen Kilmer, Investor Relations, Lance Alstodt, Chairman and Chief Executive Officer, Rob Kristal, Chief Financial Officer, and Francisco Silva, Vice President-Research and Development. Participating in the call were analysts Michael Okunewitch from Maxim Group and Elemer Piros from Rodman & Renshaw.
Company Participants
- Stephen Kilmer: Investor Relations
- Lance Alstodt: Chairman and Chief Executive Officer
- Rob Kristal: Chief Financial Officer
- Francisco Silva: Vice President-Research and Development
Conference Call Participants
- Michael Okunewitch: Maxim Group
- Elemer Piros: Rodman & Renshaw
The call began with the operator welcoming everyone and reminding them that the conference was being recorded. The participants were all in a listen-only mode at the start of the call.
Company Performance
Lance Alstodt, the CEO, started the call by discussing the company’s financial results for Q4 2024. He highlighted that the company had achieved record revenue growth, with a 35% increase year over year. The net loss for the quarter was lower than the previous year, indicating improving profitability. Rob Kristal, the CFO, then went into detail about the financials, providing a breakdown of revenue by product line and discussing the company’s cash position and cash flow.
Product Development
Francisco Silva, the VP-Research and Development, provided an update on the company’s product pipeline. He discussed the progress of their lead product, BRTX-135, which is a regenerative medicine product for spinal cord injuries. He also mentioned that they were making good progress on their new product, BRTX-150, which is a topical treatment for diabetic foot ulcers. Silva also mentioned that they had filed a patent application for a new product, BRTX-200, which is a regenerative medicine product for tendon injuries.
Analyst Questions
The call then opened up for questions from the analysts. Michael Okunewitch from Maxim Group asked about the potential market size for BRTX-135 and the competition. Lance Alstodt responded by stating that the market for spinal cord injuries was large and growing, and that they believed they had a competitive advantage due to their proprietary technology. Elemer Piros from Rodman & Renshaw asked about the timeline for regulatory approval for BRTX-135. Francisco Silva answered that they were currently in the pre-INDI stage of the regulatory approval process and expected to file an INDI application in the second half of 2025.
Impact on Me
As an individual investor, the information shared during the conference call is valuable in making informed decisions about my investment in BioRestorative Therapies, Inc. The company’s financial performance, product development progress, and regulatory timeline all impact my investment decision. I will be closely monitoring the company’s future developments and financial results.
Impact on the World
BioRestorative Therapies, Inc.’s work in the field of regenerative medicine has the potential to make a significant impact on the world. Their lead product, BRTX-135, could provide a solution for individuals with spinal cord injuries, helping them to regain mobility and improve their quality of life. The company’s other products in development, such as BRTX-150 and BRTX-200, could also make a positive impact on individuals suffering from diabetic foot ulcers and tendon injuries, respectively. The advancements in regenerative medicine could also lead to new treatments and cures for other debilitating conditions.
Conclusion
BioRestorative Therapies, Inc.’s Q4 2024 earnings conference call provided valuable insights into the company’s financial performance, product development progress, and regulatory timeline. The call also highlighted the potential impact of the company’s work on individuals and the world. As an investor, I will be closely monitoring the company’s future developments, and I am excited about the potential of their products to make a positive impact on people’s lives.
